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Abstract
Background: Public-private partnerships (PPP) could be effective in scaling up services. We
estimated cost and cost-effectiveness of different PPP arrangements in the provision of tuberculosis
(TB) treatment, and the financing required for the different models from the perspective of the
provincial TB programme, provider, and the patient.
Methods: Two different models of TB provider partnerships are evaluated, relative to sole public
provision: public-private workplace (PWP) and public-private non-government (PNP). Cost and
effectiveness data were collected at six sites providing directly observed treatment (DOT).
Effectiveness for a 12-month cohort of new sputum positive patients was measured using cure and
treatment success rates. Provider and patient costs were estimated, and analysed according to
sources of financing. Cost-effectiveness is estimated from the perspective of the provider, patient
and society in terms of the cost per TB case cured and cost per case successfully treated.
Results: Cost per case cured was significantly lower in PNP (US $354–446), and comparable
between PWP (US $788–979) and public sites (US $700–1000). PPP models could significantly
reduce costs to the patient by 64–100%. Relative to pure public sector provision and financing,
expansion of PPPs could reduce government financing required per TB patient treated from $609–
690 to $130–139 in PNP and $36–46 in PWP.
Conclusion: There is a strong economic case for expanding PPP in TB treatment and potentially
for other types of health services. Where PPPs are tailored to target groups and supported by the
public sector, scaling up of effective services could occur at much lower cost than solely relying on
public sector models.
Background
In line with the global tuberculosis-related Millennium
Development Goals to halt and begin to reverse the inci-
dence of tuberculosis (TB) by 2015, the Stop TB Partner-
ship set targets to halve TB prevalence and death by 2015
[1]. To achieve and sustain these targets, a variety of pro-
vision and financing models needs to be considered in
developing country health systems. Even with strength-
ened public health provision, the resulting outcomes may
not be as expected. Recent analysis of tuberculosis (TB)
control goals found that despite broad coverage through
public programmes, proportionate increases in case-
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detection rates were not achieved. Projections suggest that
at current rates, even if there were 100% global coverage
by DOTS – the internationally recommended control
strategy for TB, only half of new infectious cases would be
detected [2]. Key reasons for this are that patients do not
have access to public health facilities or seek care from
providers not linked to national programmes or the pub-
lic health system – such as private doctors working in their
own facilities or for employer health services [2,3]. Private
TB treatment provision has been characterised by limited
notification of cases from the private sector, inappropriate
drug regimens, and unknown treatment outcomes [4,5].
Public sector collaboration with private providers can
range from provision of information and education to for-
mal public-private partnerships (PPPs) with small-scale
contracting of service components or larger-scale sharing
of health care provision and financing [6-9]. PPPs seek to
complement rather than substitute for public health serv-
ices. Partnerships with traditional healers, community-
based organisations and private practitioners can provide
a number of benefits, including increased numbers of
people receiving services, leveraging of additional
resources, improved private provider technical capacity,
and adherence to national protocols helping to minimise
drug resistance [8].
South Africa is one of several countries where partnerships
between the public and private sectors have been recog-
nised as a policy objective [10], with the National Treas-
ury developing its own guidelines for PPPs related to
design, procurement and implementation [11]. In
response to the dual TB/HIV epidemic, the national tuber-
culosis programme has began to collaborate with differ-
ent private providers in the provision of TB treatment.
This study explores cost and cost-effectiveness of different
existing PPP arrangements for TB DOTS provision. The
financing required for the different models from the per-
spective of the provincial TB programme, provider, and
the patient are also estimated. Previous economic studies
have shown a reduction in costs and improvement in cost-
effectiveness of DOTS through decentralisation and
strengthened community-based care [12-18]. Besides the
study on the cost-effectiveness of two public-private mix
pilot projects in India [19] to-date there have been no
published studies on the cost-effectiveness of PPP involv-
ing private providers for the purposes of TB diagnosis and
treatment, nor studies on the public sector financing
requirements for any type of PPP – the latter is critical if
considering the potential scale-up or replication of PPPs.
Methods
Background
The South African National TB Control Programme
adopted the DOTS strategy in 1996. South Africa has
achieved the WHO target rate of 70% case detection, but
despite DOTS population coverage of 93% in 2004, the
treatment success rate of 67% [20] remains well below the
WHO target of 85%. The TB epidemic is fuelled by the
HIV epidemic with over 6.5 million people infected with
HIV in South Africa in 2002 [21], and 60% of TB adult
patients also HIV positive [20].
Models of provision
Three different models of DOT provision were evaluated
for different target groups: purely public, public-private
workplace partnership (PWP), and public-non-govern-
mental organisation partnership (PNP). The justification
for using three models as case studies was that they com-
plement each other by demonstrating a range of models
of provision, all of which may be relevant in particular set-
tings. In the public model, patients are diagnosed and
treated in public clinics, with direct observation under-
taken in the public health facilities by health workers fol-
lowing national treatment guidelines [22]. The PWP
model represents a partnership between provincial TB
programmes and mining companies where the
employer's occupational health services are either reim-
bursed per patient day or receive free drugs for each TB
patient treated in their clinics. The type of reimbursement
depends on the provincial regulations. Mining companies
were selected, as there is a long history of TB treatment in
the industry. The PNP model is a partnership between
provincial TB programmes and non-governmental organ-
isations (NGOs) providing community-based DOT in
which these NGOs are paid a monthly sum per patient to
manage community-based TB programmes. In this
model, patients are diagnosed and monitored in public
clinics for the first 10 days. Subsequent treatment is
directly observed by community health worker 'treatment
supporters' in the community. In addition to the funding
from the provincial TB control programme, these NGOs
receive funding from other sources such as charities and
donors. In return for payments from provincial TB pro-
grammes both private partners are required to follow
national treatment guidelines, complete and submit
standardised quarterly reports to district TB coordinators,
and liaise with district public health facilities.
Site selection
For each type of provision model, 2 sites were selected
(Table 1). Sites were identified using key informant inter-
views with provincial TB programme officials, and then
selected by purposive sampling according to their availa-
bility, urban-rural locations, different reimbursement
mechanisms, and willingness to participate in the study.
Differentials among sites in terms of TB incidence and
HIV prevalence reflected the variation in target popula-
tions reached by the PPPs.Procedure
Data collection was undertaken between March 2002 and February 2003. Written con-
sent was obtained from all the study providers. A verbal patient consent was also sought.
Ethical approval was obtained from both the University of Cape Town and London
School of Hygiene and Tropical Medicine ethical committees.
Cost and cost-effectiveness
The cost analysis was retrospectively undertaken from a provider perspective and a soci-
etal perspective. Costs were collected for a 12-month period in each facility between
2000 and 2001. Average, rather than marginal, economic costs were assessed, which are
more relevant for national policy [23]. An ingredients-based costing methodology was
used where quantities of resources were multiplied by their respective prices to obtain
total costs. Capital costs were annualised using life expectancies of 30 years for buildings,
10 years for equipment, 5 years for vehicles and training, and the standard discount rate
of 3% [24].
Methods used for measuring, identifying and valuing the costs of TB treatment are given
in Table 2. The average cost of managing a new smear-positive patient from diagnosis to
completion of treatment for each site was calculated by multiplying the average cost of
each treatment component by the number of times the cost was incurred according to the
site-specific clinic protocols.
Patient costs (time and travel costs) were estimated using a retrospective structured
patient interview. A sample of 20 randomly chosen patients in each site was used due to
time constraints. No patients were interviewed in the PWP model as DOT is provided in
the workplace. Patient costs of seeking care prior to the facility where they were inter-
Table 1: Key characteristics of each site
Model/Site PWP model PNP model Purely public model
Site 1 (N = 95) Site 2 (N = 423) Site 3 (N = 355) Site 4 (N = 50) Site 5 (N = 85) Site 6 (N = 174)
Type of provision Private workplace Private workplace Private non-governmental Private non-governmental Public Public
Type of facility Occupational health clinic Occupational health clinic Clinic working closely with a 
local NGO
Clinic working closely with a 
local NGO
Health clinic Health clinic
Location (Province) Near large rural town in 
North West
Near small rural town in Free 
State
Urban informal settlement in 
Western Cape
Rural informal settlement in 
Western Cape
Small rural town in Western 
Cape
Urban city area in Western 
Cape
Population served Low income workers, 
predominantly male
Low income workers, 
predominantly male
Low income residents, male 
and female adults, high 
unemployment
Low income residents, male 
and female adults, high 
unemployment
Low income residents, male 
and female adults, high 
unemployment
Low income residents, male 
and female adults, high 
unemployment
TB incidence per 100 000 
population*
1 073 3 012 439 149 169 176
Approximated HIV 
prevalence in the study 
population**
(approx) 44% (approx) 48% (approx) 39% (approx) 36% (approx) 29% (approx) 23%
Overall TB service range† Surveillance for TB, diagnosis 
and treatment
Surveillance for TB, diagnosis 
and treatment
Diagnosis, treatment, and 
social support
Diagnosis, treatment, and 
social support
Diagnosis and treatment Diagnosis and treatment
Case finding Annual radiological screening; 
passive, and contact tracing
Annual radiological screening; 
passive, and contact tracing
Passive Passive Passive Passive
Diagnosis Sputum smears; all patients 
with suspected pulmonary TB 
should have 1 sputum 
specimen submitted for 
culture
Sputum smears; all patients 
with suspected pulmonary TB 
should have 1 sputum 
specimen submitted for 
culture
Sputum smears; 1 sputum for 
culture if smear negative at 
diagnosis and unresponsive to 
a course of antibiotics
Sputum smears; 1 sputum for 
culture if smear negative at 
diagnosis and unresponsive to 
a course of antibiotics
Sputum smears; 1 sputum for 
culture if smear negative at 
diagnosis and unresponsive to 
a course of antibiotics
Sputum smears; 1 sputum for 
culture if smear negative at 
diagnosis and unresponsive to 
a course of antibiotics
DOT system in place Hospitalisation for the first 7 
days followed by DOT by 
nurses in the occupational 
clinics
DOT by nurses in the 
occupational health clinics
DOT by nurses in the public 
clinic for the first 10 days 
followed by DOT by 
'treatment supporters' in the 
community
DOT by nurses in the public 
clinic for the first 10 days 
followed by DOT by 
'treatment supporters' in the 
community
DOT by nurses in the public 
clinic
DOT by nurses in the public 
clinic
* Source for TB prevalence: providers' annual reports.
** Approximated by the clinic staff as no specific prevalence studies undertaken in clinic target populations. One of the reasons for higher HIV prevalence in sites 1 and 2 could be attributed to better case detection and 
follow-up in the PWP sites.
† Due to resource constraints, retrieval of defaulters is rarely done in the public sector. In the PNP model, if a patient does not attend, treatment supporters are expected to visit the patient's home within 24 hours and to 
report this to the public clinic.
In the PWP model, compliance rate is extremely high mainly because of the system of 'parading' (a patient is not allowed to work if defaulting) which is in place in the mining companies where a patient has no choice but 
adhere to the treatment.Cost Effectiveness and Resource Allocation 2006, 4:11 http://www.resource-allocation.com/content/4/1/11
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viewed were excluded from the analysis. Time costs were
converted to a monetary value based on the average
income reported by the patients interviewed [24]. Diagno-
sis and treatment of TB are free of charge to patients in all
study sites.
To calculate the effectiveness measures, the cohort of all
new smear-positive TB patients who started treatment
during the 12-month costing period was followed to
obtain the treatment outcomes. New smear-positive cases
were selected because they are the most infectious cases,
and therefore have the highest public health importance;
the South African DOTS strategy focuses primarily on
improving the cure rate among new patients; and data on
these cases were readily obtainable. The cost-effectiveness
ratio was calculated for each model of provision by divid-
ing cost by the unit of effect and compared with each
other. As these partnership models use resources from
three different sources (provider, patient and govern-
ment), both a provider and societal perspective is adopted
for the cost-effectiveness analysis.
Sensitivity analyses
To reflect the uncertainty inherent in the analysis, four
univariate sensitivity analyses were performed: using
alternative assumptions regarding provider costs (reduc-
tion of 50% of value of staff time in baseline analysis due
to a possibility that staff time could have been overesti-
mated); using alternative assumptions regarding patient
costs (limits of 95% confidence interval); variation in dis-
count rates (3% below and above the rate used in baseline
analysis); and adjusting effectiveness data by the death
rate in order to explore the importance of different HIV
prevalence across sites. Effectiveness was recalculated by
adjusting the total number of patients in the cohort by the
total number of deaths in the same cohort. Different
assumptions about provider and patient costs were exam-
ined because they constitute the major costs. A multivari-
Table 2: Methods used for measuring, identifying and valuing the costs of TB treatment
Type of cost Identification Measurement Valuation
Categories Costing method Sources of data Valuation method Sources of data
Recurrent
Personnel Administration and 
management, clinical 
staff (doctors, nurses, 
lay workers*), and 
support staff 
(cleaning)
Percentage of time 
spent on different 
activities
Observation** and 
semi-structured 
interviews with 
providers
Total remuneration 
package costs
Provider expenditure 
reports
Supplies Sputum and culture 
tests, x-rays and drugs
Quantity consumed Patient records Market prices Provincial and private 
laboratories and 
pharmacy price lists
Vehicle operating and 
maintenance
Vehicle running costs Number of kilometres 
travelled
Vehicle logbook, 
interview with clinic 
manager
Actual expenditure on 
fuel, oil and 
maintenance
Automobile 
Association rates
Building operating and 
maintenance
Overheads (water, 
electricity, telephone, 
fax, stationeries etc)
Proportion of total 
visits for which TB 
patients accounted
Actual costs from 
facility records, 
interview with clinic 
manager
Actual expenditure Provider expenditure 
reports
Capital†
Buildings Offices, clinics and 
hospitals
Proportion of total 
visits for which TB 
patients accounted
Interview with clinic 
manager
Replacement prices CSIR Building and 
Construction 
Technology
Equipment Furniture, medical and 
non-medical 
equipment
Proportion of total 
visits for which TB 
patients accounted)
Interview with clinic 
manager
Replacement prices Local manufacturers
Vehicles Vehicles used for TB 
patients
Vehicle utilisation (km 
travelled)
Vehicle log book, 
interview with clinic 
manager
Replacement prices Local car dealers
Training Community 
"treatment 
supporters" training
Number of treatment 
supporters trained
Actual costs from 
NGO records
Actual expenditure Provider expenditure 
reports
* Average cost 'treatment supporter' visits was based on the NGO payment per visit.
** Observation was used to determine clinic staff time spent on each type of visit made by adults. No variations in terms of the HIV status and 
gender of the patient were done.
† Life expectancies of buildings were 30 years, equipment 10 years, vehicles and training 5 years, and the standard discount rate of 3% (24).Table 3: Average provider costs (% of total), mean patient costs (95% confidence interval) and financing (% of total), US$*
Average provider costs PWP model PNP model Purely public model
Site 1 Site 2 Site 3 Site 4 Site 5 Site 6
N = 95 N = 423 N = 355 N = 50 N = 85 N = 174
Hospital stay** 220 (34%) N.A.†† N.A. N.A. N.A. N.A.
Health clinic visits for 
monitoring**
14 (2.1%) 18 (2.4%) 23 (9%) 24 (9%) 19 (4%) 20 (3%)
Health clinic visits for DOT** 334 (51%) 301 (40%) 36 (14%) 39 (16%) 426 (84%) 485 (85%)
Visits to 'treatment 
supporters'**
N.A. N.A. 55 (22%) 55 (22%) N.A. N.A.
Sputum smears† 12 (1.8%) 14 (1.8%) 16 (7%) 16 (7%) 16 (3%) 16 (3%)
Sputum culture† 16 (2.4%) 17 (2.3%) N.A. N.A. N.A. N.A.
Drugs 46 (7%) 383 (52%) 46 (18%) 46 (18%) 46 (9%) 46 (8%)
X-rays† 12 (1.8%) 11 (1.5%) N.A. N.A. N.A. N.A.
Overall supervision of 
community-based programme
N.A. N.A. 74 (29%) 72 (28%) N.A. N.A.
Training for community 
'treatment supporters'
N.A. N.A. 1 (0.4%) 1 (0.4%) N.A. N.A.
Total cost per patient 654 744 251 253 507 568
Mean patient cost
Visits to clinic for monitoring 
and DOT
Travel cost N/A N/A 2.1 (1.7–2.4) 2.6 (2.3–3.2) 26.2 (25.1–27.6) 20.3 (18.6–23.8)
Time cost N/A N/A 6.2 (4.0–8.3) 5.9 (4.6–6.5) 75.6 (71.8–78.2) 101.9 (94.4–115.1)
Visits to 'treatment 
supporter' for DOT
Travel cost N/A N/A 0 0 N.A. N.A.
Time cost N/A N/A 30.9 (23.6–36.8) 28.2 (24.9–30.5) N.A. N.A.
Total cost per patient N/A N/A 39.2 (28.3–47.5) 36.7 (31.8–40.2) 101.8 (96.9–105.8) 122.2 (113.0–138.9)
Financing of treatment 
cost
Public provider N.A. N.A. 59 (20%) 63 (20%) 445 (73%) 506 (73%)
Private provider 609 (93%) 708 (95%) 121 (42%) 114 (39%) N.A. N.A.
Provincial TB programme‡ 46 (7%) 36 (5%) 71 (24%) 76 (27%) 62 (10%) 62 (9%)
Patient N.A. N.A. 39 (13%) 37 (13%) 102 (17%) 122 (18%)
Total cost per patient 654 744 290 290 609 690
* Cost data from 2001. Average exchange rate prevailing in 2001 US$1 = R8.57.
** Expected number of visits/hospital days for each site is as follows: 7 hospital days for site 1; 3 visits for monitoring at each site except at site 1 where there are only 2 such visits; 130 visits for DOT (sites 2, 5 and 6), 123 visits 
for DOT (site 1), and 10 visits for DOT (sites 3 and 4); 120 visits to 'treatment supporter' (sites 3 and 4).
† Expected number of diagnostic tests for each site: 4 sputum smears (site 1), 7 sputum smears (site 2), and 4 sputum smears (sites 4–6); 1 sputum culture (sites 1 and 2); 3 X-rays (sites 1 and 2).
†† N.A. = not applicable.
‡ Provincial TB programme covered the cost of drugs in all the sites except in site 2 where a reimbursement on a patient day basis was provided. In addition to the drugs, the programme also covered the cost of diagnostic tests 
in sites 3–6.
ate sensitivity analysis, where estimates of provider cost and effectiveness adjusted by the
death rate are varied at the same time, was also performed.
Results
Average cost per patient treated
The cost per TB patient treated varied across the models of treatment provision (Table 3),
with the highest costs for the PWP models (US$ 654–744) reflecting different protocols
related to hospitalisation (site 1) and procurement of drugs. In site 2, the only site with-
out public financing of drugs, 52% of the entire treatment cost was drugs. The PNP modelCost Effectiveness and Resource Allocation 2006, 4:11 http://www.resource-allocation.com/content/4/1/11
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had the lowest cost per patient treated and was less than
half of that found in the PWP model. DOT was the most
significant cost in public clinics (84–85%) and 40–51%
of costs in PWP sites. The largest cost component for PNP
was the overall supervision of the programme (28–29%).
The cost to the patient in the purely public model was
between 2.6 and 3.3 times higher than the PNP model
reflecting less time that a patient had to spend getting the
treatment in the community and lower transport cost
(Table 3).
The costs of TB treatment were largely financed by the
main provider in each site (Table 3). PWP providers
financed 93–95% of the total cost with a small 5–7% con-
tribution required from the provincial TB programme. In
contrast, the provincial TB programme contributed 24–
27% of financing towards PNP sites, with the public sec-
tor also paying for another 20% of costs. However, in
budgetary terms this meant that the provincial TB pro-
gramme contributed only up to twice the amount of fund-
ing to PNP sites as it did for PWP, reflecting the much
lower cost per patient treated ($290) in the PNP sites ver-
sus the public or PWP sites.
Treatment outcomes
Table 4 shows treatment outcomes for all new smear-pos-
itive cases in the cohort. The treatment success rate ranged
between 74% (site 6) and 89% (site 5) and the cure rate
ranged between 65% (site 3) and 87% (site 5). The major
influence on effectiveness were high mortality rates of
12% and 11% in sites 1 and 2 respectively, and high
defaulting rates of 24% and 16% (and so lower cure rates)
in sites 3 and 6 respectively which were the only 2 urban
sites. No one model performed unambiguously better
than the others.
Cost-effectiveness
A provider-only perspective shows the most cost-effective
TB treatment was the PNP model reflecting both lower
cost per patient treated and relatively higher treatment
success and cure rates (Table 4). The least cost-effective TB
treatment was the PWP model, where sites achieved rela-
tively higher successful treatment success and cure rates,
but the average costs per patient treated were the highest.
From the patient's perspective, the most cost-effective TB
treatment was the PWP model (TB treatment was work-
place-based and the employer covered the cost of trans-
port), followed by the PNP model (TB treatment was
community-based and accessible to the patient). The least
cost-effective was the purely public model, reflecting long
waiting hours and poor geographical accessibility of pub-
lic clinics. From the social perspective, the PNP model
remained the most cost-effective model of all the models
of provision. However, from a societal perspective, there
were similar ranges for cost-effectiveness between the
PWP model and the purely public model.
Sensitivity analyses
The results were robust in sensitivity analyses (Table 5)
with cost and cost-effectiveness assumptions most sensi-
tive to valuation of staff time. The relative rankings
remained the same. Sensitivity analysis using the number
of registered patients adjusted by the number of the
patients who died during the treatment showed that
results were not sensitive to plausible variability in the
effectiveness data. Cost-effectiveness in the higher HIV
prevalence sites improved considerably when compared
to other study sites.
Discussion
This study provides evidence on the cost-effectiveness of
different PPP models for the provision of TB treatment in
South Africa. In the two PPP models, increased commu-
nity involvement and availability of treatment at a work-
place were more affordable to the public sector. The
effectiveness was also better in the PPP models, suggesting
that the public-private models of provision are more effec-
tive than the purely public model. This may be due to
superior quality of care provided in public-private settings
[25]. Overall, the PNP model was consistently the most
cost-effective model, similar to results elsewhere evaluat-
ing community-based models [13-19]. However, these
results are preliminary due to a limited number of sites
available for each model and therefore cannot provide
definite conclusions. The study is context-specific and
exploratory in its nature as it evaluates exiting models and
does not provide any definite results.
The new costs associated with the community-based treat-
ment to the public sector were small in comparison with
the cost of DOT in public clinics. The incentive paid to
community treatment supporters (on average US$ 0.3 per
visit) was much lower than the average cost of a clinic visit
(on average US$ 3.5 per visit). The availability of the treat-
ment at a workplace and in the community resulted in
substantial savings to the patient. In addition to the cost
reduction to the public sector, by providing TB treatment
to poorer community members and employees, the treat-
ment became more accessible and convenient for patients
in both study populations reducing costs to the patient by
64%–100%.
It is also important to consider where the employer-based
and community-based approaches are of greatest rele-
vance. Arguably, the employer-based TB treatment is most
appropriate in companies which employ a large number
of people, where occupational health clinics exist and
where TB is an occupational health problem, as it is in theTable 4: Treatment outcome and cost-effectiveness (CE) for each model of treatment provision in 2001 US$*
Treatment outcome** PWP model PNP model Purely public model
Site 1 Site 2 Site 3 Site 4 Site 5 Site 6
N = 95 N = 423 N = 355 N = 50 N = 85 N = 174
Successfully treated† 83 (87%) 368 (87%) 283 (80%) 41 (82%) 76 (89%) 129 (74%)
Cured†† 79 (83%) 321 (76%) 231 (65%) 41 (82%) 74 (87%) 121 (69%)
Failed‡ 1 (1%) 4 (1%) 3 (1%) 1 (2%) 0 1 (1%)
Died‡‡ 11 (12%) 47 (12%) 13 (4%) 4 (8%) 1 (1%) 4 (2%)
Interrupted§ - - 56 (15%) 4 (8%) 8 (10%) 40 (23%)
CE from the provider 
perspective
Total cost of treating patient 654 744 251 253 507 568
Treatment success rate§§ 87 87 80 82 89 74
Cure rate|| 83 76 65 82 87 69
Cost per new smear-positive 
patient successfully treated
752 855 314 308 570 767
Cost per new smear-positive 
patient cured
788 979 386 308 583 823
CE from the patient 
perspective
Total cost of treating patient N.A. N.A. 39 37 102 122
Treatment success rate 80 82 89 74
Cure rate 65 82 87 69
Cost per new smear-positive 
patient successfully treated
49 45 115 165
Cost per new smear-positive 
patient cured
60 45 117 177
CE from the societal 
perspective
Total cost of treating patient|| 
||
654 744 290 290 609 690
Treatment success rate 87 87 80 82 89 74
Cure rate 83 76 65 82 87 69
Cost per new smear-positive 
patient successfully treated
752 855 362 354 684 932
Cost per new smear-positive 
patient cured
788 979 446 354 700 1 000
* Cost data from 2001. Average exchange rate prevailing in 2001 US$1 = R8.57.
** Source: Reports submitted to the provincial TB programmes.
† The sum of those patients who were cured plus those who completed treatment but without laboratory proof of cure.
†† Patients who were smear negative at the end of treatment.
‡ Patients who remained or become again smear-positive at 5 months or later during treatment. Patients who were 'transferred out' are not included in the denominator (to be in line with international and national reporting 
requirements, this category of TB patients will in future be included in the denominator of the reporting district where they were initially registered). The number of patients who were 'transferred out': 1 (site 1), 4 (site 2), 31 
(site 3), 9 (site 4), 16 (site 5) and 35 (site 6).
‡‡ Patients who died for any reason during the course of TB treatment.
§ Patients whose treatment was interrupted for 2 months or more.
§§ Estimated as a ratio between the number of new smear-positive patients registered and the number of new smear-positive patients successfully treated.
|| Estimated as a ratio between the number of new smear-positive patients registered and the number of new smear-positive patients cured.
|| ||This represents a sum of provider and patient costs for each site.Table 5: Sensitivity analyses
PWP model PNP model Purely public model
Site 1 Site 2 Site 3 Site 4 Site 5 Site6
Alternative estimates of provider costs (staff time)
• % divergence from base-case provider cost estimate -15% -13% -8% -8% -24% -28%
• % divergence from base-case provider cost-effectiveness estimate -15% -13% -8% -8% -24% -28%
Lower limit patient cost
• % divergence from base-case patient cost estimate N.A.* N.A. -5% -5% -5% -5%
• % divergence from base-case patient cost-effectiveness estimate N.A. N.A. -4% -3% -1% -1%
Upper limit patient cost
• % divergence from base-case patient cost estimate N.A. N.A. +5% +5% +5% +5%
• % divergence from base-case patient cost-effectiveness estimate N.A. N.A +3% +0.2% +0.6% +2%
0% discount rate
• % divergence from base-case provider cost estimate -3% -3% -3% -3% -3% -3%
• % divergence from provider cost-effectiveness estimate -2% -0.6% -0.5% -2% -1% -0.5%
6% discount rate
• % divergence from base-case provider cost estimate +3% +3% +3% +3% +3% +3%
• % divergence from provider cost-effectiveness estimate +3% +2% +2% +3% +2% +2%
Effectiveness adjusted by the death rate**
• % divergence from base-case treatment success rate -12% -11% -4% -8% -1% -2%
• % divergence from base-case societal cost-effectiveness estimate (treatment 
success rate)
-12% -11% -4% -8% -1.6% -2.5%
• % divergence from base-case cure rate -12% -11% -4% -8% -1% -2%
• % divergence from base-case societal cost-effectiveness estimate (cure rate) -12% -11% -4% -8% -1% -2%
Multivariate analysis (estimates of provider cost and effectiveness 
adjusted by the death rate are varied at the same time)
• % divergence from base-case provider cost estimate -15% -13% -8% -8% -24% -28%
• % divergence from base-case cure rate -12% -11% -4% -8% -1% -2%
• % divergence from base-case societal cost-effectiveness estimate -25% -23% -11% -15% -25% -30%
* N.A. = not applicable.
**Effectiveness was re-calculated by adjusting the total number of patients in the cohort by the total number of deaths in the same cohort. In this case, the treatment success rate = [number of successfully treated patients/
(total number of patients – number of patients who died during treatment)] * 100. For example, in site 1, the treatment success rate adjusted by the death rate = [83/(95 - 11)] * 100 = 99%.
mining industry. In the case of the community-based TB treatment, it is most appropriate
in areas where public sector clinics are already working at capacity; where clinic-based
care is not achieving high cure rates; where geographical access to health facilities for
patients is poor; and where more affordable but still cost-effective approaches are
required due to health service budget cuts and/or increases in the number of TB cases. The
different ways in which community-based TB treatment can be implemented depend on
the level of socio-economic development, the degree of social mobilisation for TB among
other health activities, and the particular cultural setting (Maher et al 1999). While the
principles of community contribution of TB are generalisable (e.g. close links between
the general health services, TB control programme and community-based NGOs), the
details of how this model of service delivery is designed and implemented will depend
largely on the specific setting.
The study has a number of limitations. Non-randomised purposive sampling was used to
identify sites that reflected communities and locations where PPPs are currently in place.
Thus the sites varied significantly in terms of TB incidence due to the nature of the PPP
target groups. Although efforts were made to try and select sites with similar HIV preva-
lence rates, the nature of the PPP target groups and scarcity of data on HIV prevalence
made this difficult. As there is a higher mortality rate for HIV+ TB patients, we were not
able to control for the fact that TB treatment outcomes might have been poorer in sites
with a higher HIV prevalence rate than in sites with a lower HIV prevalence rate. This
could underestimate the cost-effectiveness at higher HIV/TB incidence sites. However, it
is difficult to discuss the importance of HIV prevalence differences on the study results as
HIV prevalence rates are based on estimates by the clinic staff. The study results might
also be different if smear negative cases were selected. The PPPs were all relatively well
functioning (with cure rates well above the South African average of 55%). The purposive
sampling may have led to identification of better-functioning PPPs, which may suggest
that results are optimistic. The conventional practice of using average reported incomes
among a sample of patients is used to value patient time. This might have under or over-
estimated true costs. Finally, whilst important, the time cost of identifying, selecting, ini-
tiating and sustaining different PPPs, and the "stewardship" costs, such as ensuring that
the private partners follow TB treatment guidelines, to government were not included inCost Effectiveness and Resource Allocation 2006, 4:11 http://www.resource-allocation.com/content/4/1/11
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the analysis. We estimate these costs to be around US
$35,000 per year per province (this is the salary cost of a
middle-level manager whose main responsibility would
be to manage PPPs for the provision of TB). In addition, a
range of incentives should be used to encourage private
sector participation in partnership with the government
for the provision of TB treatment. While recognising that
'getting incentives right' is important in any principal-
agent relationship, monitoring and evaluation of the part-
nerships, however, may not always be easy and other fac-
tors, such as levels of trust and perceptions of relative
risks, may potentially play an essential role in underpin-
ning efficient public-private relationships.
Conclusion
Overall, the results suggest there is a strong economic case
for expanding PPP involvement in TB treatment in the
process of scaling up. The cost per new patient treated to
government could be reduced by enhanced partnership
between the private and public sectors. Expansion of PPPs
could potentially lead to reduced government sector
financing requirements for new patients: government
financing would require $609–690 per new patient
treated, in contrast to PNP sites which would only need to
$130–139 per patient (almost a five-fold reduction in
costs), and $36–46 (a fifteen fold reduction) with the
PWP model. The study models are comparable in that
they follow the same TB treatment protocol, are similar in
terms of key social, economic and demographic character-
istics, and provide care to the lower-income populations.
The major caveat to using the study results in making pol-
icy recommendations is that it was based on a small
number of study sites. Whilst including such a small sam-
ple of sites should not have influenced losing any rigour,
the results should be interpreted as preliminary.
Tuberculosis treatment provided through the PPPs also
seems to be more accessible and convenient for patients in
both study populations. Through partnership with the
government, mining companies and community-based
NGOs can take most of the responsibility for their own
employees and associated communities respectively. The
PWP model appears to be more sustainable than the PNP
model, mainly due to dependency of the NGOs on exter-
nal financing. Moreover, employers have an economic
incentive to keep the workforce healthy.
This study evaluated different models of provision for dif-
ferent study populations. Ideally, an experiment should
be set up to compare different models for the same popu-
lation. In urban areas, both PNP and public sites had
greater default rates. This may well improve by using PPPs
involving other types of private providers such as private
practitioners in urban areas. Currently these types of
arrangements are limited relative to other parts of the
world [26-28].
Expansion may require increased investment in the PPPs,
but they seem to be capable of delivering important
improvements in the affordability and efficiency of TB
treatment, and improving the South African health sys-
tem's capacity to cope with the impact of the HIV/AIDS
epidemic. Regardless of the model, the provincial TB pro-
grammes had to finance some proportion of the total cost
per patient (although almost 50% lower for PWP mod-
els). Managing PPPs, however, is challenging as they
embody a complex set of relationships between public
and private actors and require careful monitoring [8].
These findings could also be applicable to PPPs in the pro-
vision of other services such STI treatment [29] and repro-
ductive health services [30]. PPPs should be seen as
complementary to public services as the different models
serve different target groups. These results show that
where PPPs are tailored to the context and well-supported
by the public sector, scaling-up of effective services could
occur at much lower cost relative to solely scaling up tra-
ditional public sector models. However, an assessment of
the resources required from the government for training,
monitoring and quality control of PPPs is crucial, and fur-
ther research into financial sustainability of the NGOs is
needed.
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